BioAtla, Inc. (BCAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
BCAB Stock Price Chart Interactive Chart >
BCAB Price/Volume Stats
| Current price | $2.47 | 52-week high | $12.15 |
| Prev. close | $2.49 | 52-week low | $2.01 |
| Day low | $2.43 | Volume | 94,438 |
| Day high | $2.51 | Avg. volume | 776,002 |
| 50-day MA | $3.54 | Dividend yield | N/A |
| 200-day MA | $6.00 | Market Cap | 92.89M |
BioAtla, Inc. (BCAB) Company Bio
BioAtla LLC develops conditionally active biologic antibody therapeutics. The firm's technologies include conditionally active biologics, comprehensive integrated antibody optimization, CPE and CPS, gigamab, and versitop. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Latest BCAB News From Around the Web
Below are the latest news stories about BIOATLA INC that investors may wish to consider to help them evaluate BCAB as an investment opportunity.
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business HighlightsSAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2022 and provide business highlights. Conference Call |
BioAtla Announces Change in Executive LeadershipSAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as Chief Executive Officer at Viatris (Nasdaq: VTRS), a large, global healthcare pharmaceutical company. Scott will continue his relationship with BioA |
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced AdenocarcinomaFollowing the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administrati |
Recent uptick might appease BioAtla, Inc. (NASDAQ:BCAB) institutional owners after losing 56% over the past yearIf you want to know who really controls BioAtla, Inc. ( NASDAQ:BCAB ), then you'll have to look at the makeup of its... |
BioAtla Provides Clinical Program Updates and Upcoming 2023 MilestonesMecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registrational study is being initiated; anticipate first patient dosed this quarter BA3071 Phase 1 study ongoing with first two dose escalation cohorts completed; third cohort (70mg) on-going CAB clinical programs continue |
BCAB Price Returns
| 1-mo | -33.60% |
| 3-mo | -70.38% |
| 6-mo | -71.54% |
| 1-year | -57.19% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -70.06% |
| 2022 | -57.97% |
| 2021 | -42.28% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...